Bispecific antibody · Immune activation, directed at Fc receptor-like protein 5 (FCRL5) and CD3 (CD3E) · developed by Genentech
Phase 1Most advanced trial
1Registered trials
What is Cevostamab?
Cevostamab is a bispecific T-cell engager antibody built from two single-chain variable fragments, one binding FCRH5 on tumor cells and one binding CD3 on cytotoxic T lymphocytes. By crosslinking these cells it triggers T-cell-mediated killing of FCRH5-expressing cells and is studied in multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
BFCR-4350A, RO-7187797
Drug type
Bispecific antibody
Targets
Fc receptor-like protein 5 (FCRL5), CD3 (CD3E)
Mechanism
Immune activation, directed at Fc receptor-like protein 5 (FCRL5) and CD3 (CD3E)
Pathways
T-cell activation and crosslinking, CTL-mediated tumor cell death
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.